Tag Archives: Cole Werble

FDA: From Risk Aversion to Approval Activism

During the Rutgers Business School’s annual healthcare symposium, an FDA official encouraged industry to put its drugs on the reviewing table and be prepared for good news. On a panel titled “Activist FDA: Transformation Agent,” Prevision Policy founder and former Pink Sheet editorial head Cole Werble relayed the tale of Acadia Pharmaceuticals, a San Diego-based […]
Posted in Agency Insight, Biotech, FDA, leadership, Legal, Market Access, Orphan Drugs, People, R&D, Regulatory, Strategy | Also tagged , , , , , , | 2 Comments
  • Categories

  • Meta